Ann: Chairman's Address and Presentation to AGM, page-140

You’re either not reading or not comprehending. The technology is proven, BUT the company has been so focused on trying to crack the DX industry which has massive barriers to entry (ie. Established products, controlling mega vendors, pipeline products with billions invested, regulatory approval costs, etc.). The partnerships have consistently confirmed the technology, but not the commercial viability of getting it to market.

The above has been reiterated numerous times in this forum. They need to pick an industry with reduced barrier to entry to get a commercial outcome in the near term to fund the ongoing work in DX, or abandoned the DX work altogether should they land a partnership in another industry.

There’s your honesty. There are no reasons for the megavendors to change anything in the DX industry. THey control it and don’t need to save money. The only hope (imho) is to find a challenger brand with bottomless pockets to try and crack in for a small percentage until it gains momentum and gets bought out OR be a part of an assay that doesn’t currently exist.

The POC device is an excellent example of where AMG benefits the DX end customer immensely. But ask yourself this, what are the monetary advantages to the seller of medical services and devices of a POC device? We see things through the lens of someone having a heart attack. Look at it through the lens of a medical industry employee, a hospital administrator / CEO who invested in today’s technology, or a manufacturer who spent billions on the current lab based assay. It potentially wipes out a lot of previously invested money in the value chain of services delivered. Has nothing to do with whether or not the tech works, imho.